论文部分内容阅读
目的 观察尿激酶联合化疗治疗密集包裹性恶性胸腔积液的临床疗效.方法 收集2008年6月至2012年6月之间36例化疗前、化疗中出现密集包裹性恶性胸腔积液患者,采用尿激酶溶解包裹后再行胸腔化疗与2004年6月至2008年6月40例密集包裹性恶性胸腔积液未用尿激酶患者作历史对照.结果 尿激酶治疗组29例达完全缓解(CR),缓解时间(11.2±2.3)个月,中位总生存期(0S)(14.2±3.2)个月,中位无进展生存期(PFS)(9.2±2.2)个月,3例有中度胸膜肥厚.未用尿激酶组仅7例达CR,缓解时间(4.2±1.3)个月,中位OS(4.8±0.67),中位PFS(3.1 ±0.5)月,21例有中重度胸膜肥厚伴肺功能下降.结论 尿激酶联合化疗治疗密集包裹的恶性胸腔积液与老的治疗方法相比可显著增加包裹性恶性胸腔积液患者的肺复张率,完全缓解率,无进展生存期及总生存期,且患者可获得很高的生活质量,值得在临床推广.“,”Objective To assess the efficacy of urokinase and chomotherapy in treatment of multilocular encapsulated malignant pleural effusion.Methods The observation group:patients with multilocular encapsulated malignant pleural induced by malignant pleural from June 2008 to June 2012.36 patients were treated with urokinase and chemotherapy;The history control group:40 patients from June 2004 to June 2008 were treated with intralpleural injection of chemotherapy drugs only.Results Totally 29 cases of the observation group received complete remission (CR).The complete remission time is (11.2 ±2.3) months,overall survival (OS) is (14.2 ±3.2) months,progression free survival (PFS) is (9.2 ±2.2) months,and 3 Patients is medium pleural thickening;7 cases of the control group received CR.The complete remission time is (4.2 ± 1.3) months,OS is (4.8 ± 1.3) months,PFS is (3.1 ±0.5) months.21 Patients is medium pleural thickening and pulmonary insufficiency.Conclusion intrapleural injection of urokinase and chemotherapy drugs into pleural for multilocular encapsulated malignant pleural is better than intralpleural injection of chemotherapy drugs only.